Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.

Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.

In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.